{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Astellas Pharma, Inc.
Astellas Pharma Stock Hits Day Low Amid Price Pressure, Closes at JPY 2,359.00
Astellas Pharma, Inc. saw a decline in stock price today, contrasting with the broader market trend. Despite recent downturns, the company has shown strong annual performance, with a notable return and healthy financial metrics, including a solid EBIT to Interest ratio and significant growth in net sales.
Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 2,399.50
Astellas Pharma, Inc. saw a decline in its stock price today, contrasting with the broader market's performance. Despite recent fluctuations, the company has shown strong annual returns and maintains solid financial metrics, including a high return on equity and a favorable EBIT to interest ratio.
Astellas Pharma, Inc. Shows Strong Financial Growth Amidst Flat Performance
Astellas Pharma, Inc. reported mixed financial results for the quarter ending June 2025, with significant growth in operating profit, pre-tax profit, and net profit. The company achieved its highest operating profit margin at 31.1%, benefiting from reduced raw material costs, which enhanced its overall profitability and operational efficiency.
Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 1,569.00
Astellas Pharma, Inc. saw a significant stock decline today, contrasting with the modest decrease in the Japan Nikkei 225. Over the past year, Astellas has underperformed, with a notable drop compared to the index's gains. Despite challenges, the company shows strong management efficiency metrics.
Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops 4.6%
Astellas Pharma, Inc. faced a significant stock decline today, contrasting with the broader market's performance. Over the past year, the company has seen a notable drop, despite a substantial increase in profits. Astellas maintains a strong EBIT to Interest ratio, reflecting its debt management capabilities.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
